KR910002853A - 도파민 효능제 - Google Patents

도파민 효능제 Download PDF

Info

Publication number
KR910002853A
KR910002853A KR1019900011149A KR900011149A KR910002853A KR 910002853 A KR910002853 A KR 910002853A KR 1019900011149 A KR1019900011149 A KR 1019900011149A KR 900011149 A KR900011149 A KR 900011149A KR 910002853 A KR910002853 A KR 910002853A
Authority
KR
South Korea
Prior art keywords
compound
alkyl
pharmaceutically acceptable
formula
hydrogen
Prior art date
Application number
KR1019900011149A
Other languages
English (en)
Inventor
메너트 샤우스 죤
Original Assignee
레로이 휘타커
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 레로이 휘타커, 일라이 릴리 앤드 캄파니 filed Critical 레로이 휘타커
Publication of KR910002853A publication Critical patent/KR910002853A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

내용 없음.

Description

도파민 효능제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (3)

  1. 일반식(Ⅰ)의 화합물 또는 이의 약제학적으로 허용되는 염.
    상기식에서, X는 할로, 하이드록시, 수소, C1-C4알킬 또는 일반식-NR1R2(여기서, R1및 R2는 각각 수소 C1-C6알킬, C2-C6아실 또는 -C6알킬페닐이거나, R1및 R2는 이들이 결합된 질소원자와 함께 하나 또는 두개의 질소원자, 또는 하나의 질소원자와 하나의 산소원자를 함유하는 3-내지 3원의 헤테로 사이클릭 환을 형성한다]의 그룹이고, R은 C1-C4알킬, 알릴 또는 사이클로프로필메틸이다.
  2. 제1항에 있어서, R이 프로필이고, X가 -NH2화합물.
  3. 활성 화합물로서 제1항 또는 2항에 따른 일반식(I)의 화합물 또는 이의 약제학적으로 허용되는 염 및 하나 이상의 약제학적으로 허용되는 부형제, 희석제 또는 담체를 함유함을 특징으로 하는 약제학적 제제.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900011149A 1989-07-24 1990-07-23 도파민 효능제 KR910002853A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US383673 1989-07-24
US07/383,673 US4939259A (en) 1989-07-24 1989-07-24 2-oxo-pyrido[2,3-g]quinoline derivatives

Publications (1)

Publication Number Publication Date
KR910002853A true KR910002853A (ko) 1991-02-26

Family

ID=23514174

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900011149A KR910002853A (ko) 1989-07-24 1990-07-23 도파민 효능제

Country Status (14)

Country Link
US (1) US4939259A (ko)
EP (1) EP0410641A3 (ko)
JP (1) JPH0395182A (ko)
KR (1) KR910002853A (ko)
CN (1) CN1049162A (ko)
AU (1) AU631228B2 (ko)
CA (1) CA2021314A1 (ko)
HU (1) HU207079B (ko)
IE (1) IE902674A1 (ko)
MX (1) MX21657A (ko)
NZ (1) NZ234550A (ko)
PT (1) PT94749A (ko)
RU (1) RU1836371C (ko)
ZA (1) ZA905618B (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1440286A (zh) * 2000-07-04 2003-09-03 东丽株式会社 情绪失常或焦虑的治疗或预防药
DE502005005922D1 (de) * 2005-06-21 2008-12-18 Geke Technologie Gmbh Geschoss oder gefechtskopf
FR2936710B1 (fr) * 2008-10-07 2011-01-07 Ceva Sante Animale Composition veterinaire antiprolactinique destinee aux ruminants
WO2011116282A2 (en) * 2010-03-19 2011-09-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nicotinic acetylcholine receptor agonists

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA995670A (en) * 1970-10-05 1976-08-24 Wilson S. Waring Phenanthrolines and pyrido-quinolines
US4198415A (en) * 1979-01-22 1980-04-15 Eli Lilly And Company Prolactin inhibiting octahydro pyrazolo[3,4-g]quinolines
US4235909A (en) * 1979-04-19 1980-11-25 Eli Lilly And Company Octahydro-2H-pyrrolo[3,4-g]quinolines
PH22782A (en) * 1983-02-01 1988-12-12 Sandoz Ltd Novel pharmaceutical active 1,2,3,4,4a,5,10,10a octahydrobenzo(g)quinoline derivatives
US4501890A (en) * 1983-09-26 1985-02-26 Eli Lilly And Company Trans-(±)-2,4,6-substituted-5,5a,6,7,8,9,9a,10-octahydro-pyrimido[4,5-g]quinolines
US4537893A (en) * 1984-04-27 1985-08-27 Eli Lilly And Company Octahydrothiazolo[4,5-g]quinolines and use as prolactin secretion inhibitors
DK349185A (da) * 1984-08-02 1986-02-03 Lilly Co Eli Octahydro-oxazolo(4,5-g) quinolin-forbindelser og fremgangsmaade til fremstilling heraf
US4659832A (en) * 1985-06-10 1987-04-21 Eli Lilly And Company Process for the preparation of octahydro-oxazolo [4,5-G]quinolines
US4826986A (en) * 1986-06-16 1989-05-02 Eli Lilly And Company 6-Oxo-trans-octa- and decahydroquinolines

Also Published As

Publication number Publication date
IE902674A1 (en) 1991-02-27
CN1049162A (zh) 1991-02-13
EP0410641A3 (en) 1991-04-17
JPH0395182A (ja) 1991-04-19
NZ234550A (en) 1992-03-26
US4939259A (en) 1990-07-03
AU631228B2 (en) 1992-11-19
HU207079B (en) 1993-03-01
MX21657A (es) 1993-12-01
PT94749A (pt) 1991-03-20
CA2021314A1 (en) 1991-01-25
AU5918490A (en) 1991-01-24
RU1836371C (ru) 1993-08-23
HU904584D0 (en) 1990-12-28
ZA905618B (en) 1992-03-25
EP0410641A2 (en) 1991-01-30
HUT54686A (en) 1991-03-28

Similar Documents

Publication Publication Date Title
KR920021555A (ko) 비사이클릭 라파 마이신
KR890006599A (ko) 복소환 유도체, 그의 제법 및 이를 활성성분으로 함유하는 방사선 감응제 및 항비루스제
KR910011896A (ko) 신규한 글리코펩티드 유도체
KR930019655A (ko) 종양치료 조성물 및 치료방법
KR950017957A (ko) 3, 4, 4-삼치환-피페리디닐-n-알킬카르복실레이트의 제법 및 중간체
KR890013049A (ko) 2',3'-디에옥시-2',2'-디플루오로뉴클레오사이드
KR920003968A (ko) 염증성 장 질환의 치료방법
KR920702360A (ko) 인돌 유도체
KR900003163A (ko) 시클로헥산 유도체
KR960007592A (ko) 신규한 피롤로카바졸
KR890007730A (ko) 허혈성 심질환 치료제
KR920016089A (ko) 제i형 당뇨병의 치료방법
KR900009606A (ko) 불소-함유 2-니트로 이미다졸 유도체 및 그를 함유하는 방사선 증감제
KR890014448A (ko) 아실페놀 유도체
KR860008111A (ko) 인딘과 나프탈렌 유도체의 제조방법
KR890000482A (ko) (8β)-1-알킬-6-(치환된) 에르 골린의 시클로알킬아미드
KR910002853A (ko) 도파민 효능제
KR950032183A (ko) 글루코피라노사이드 벤조티오펜
KR890008136A (ko) 항균성 9-데옥소-9a-알릴 및 프로파길-9a-아자-9a-호모에리트로 마이신 A 유도체
KR890008148A (ko) 새로운 세파로스포린 화합물 및 항균제
KR890009901A (ko) 3-히드록시-2-(4-메톡시페닐)-5-(2-메틸아미노에틸)-2,3-디히드로-5h-1,5- 벤조티아제핀-4-온 유도체, 그의 제조 및 치료에의 이용
KR920702685A (ko) 4,6-o- 히드록시포스포릴글루코사민 유도체
KR900006316A (ko) 벤조 헤테로 고리화합물 및 그 제조방법
KR890012960A (ko) 결정성 β-락탐 용매화물
KR910005860A (ko) 항간질환성 조성물

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid